-- Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR 
      for prophylactic treatment of HAE attacks; topline data anticipated in 
      3Q2026 
 
   -- Timeline for submission of NDA dossier of deucrictibant IR for on-demand 
      treatment of HAE attacks remains on-track in 1H2026 
 
   -- Enrollment ongoing in CREAATE, a pivotal study of deucrictibant for the 
      prophylactic and on-demand treatment of AAE-C1INH attacks 
 
   -- Cash and cash equivalents of EUR292 million as of December 31, 2025 

ZUG, Switzerland, April 02, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema $(HAE)$ and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.

"The positive readout of our first pivotal Phase 3 study, RAPIDe-3, at the end of 2025 was a crucial moment for Pharvaris. With the momentum of this important milestone, we continue to execute in 2026 through the anticipated NDA submission of deucrictibant IR for the on-demand treatment of HAE attacks, topline data readout of CHAPTER-3, and enrollment in CREAATE," said Berndt Modig, Chief Executive Officer of Pharvaris. "Across all our programs, Pharvaris remains committed to helping to improve standard of care for those living with bradykinin-mediated angioedema. In addition to potentially bringing deucrictibant to those with HAE type 1 and type 2, we hope to also address unmet needs of those with HAE with normal C1 inhibitor and acquired angioedema with C1 inhibitor deficiency. Our team will continue to operate in a financially disciplined manner through these key inflection points."

Recent Business Updates

Development Pipeline

   -- Topline data from CHAPTER-3 (NCT06669754) anticipated 3Q2026. Target 
      enrollment was achieved in CHAPTER-3, a randomized, double-blind, 
      placebo-controlled Phase 3 study of orally administered deucrictibant 
      extended-release (XR) tablet for the prophylaxis against angioedema 
      attacks in adults and adolescents (12 years and older) with HAE. The 
      study enrolled approximately 81 participants randomized in a 2:1 ratio to 
      receive deucrictibant XR (40 mg), which is the intended commercial 
      formulation, or placebo, once daily for 24 weeks. Pharvaris anticipates 
      announcing topline data of CHAPTER-3 in the third quarter of 2026. 
 
   -- Enrollment in CHAPTER-4 (NCT06679881) progressing as planned. CHAPTER-4 
      is a long-term, open-label extension study of orally administered 
      deucrictibant XR tablet (40 mg/day) for the prophylactic treatment of HAE 
      attacks. The goal of the study is to evaluate the long-term safety and 
      effectiveness of deucrictibant XR tablet in the prophylactic treatment of 
      HAE attacks. 
   -- Submission of U.S. New Drug Application (NDA) of deucrictibant IR for the 
      on-demand treatment of HAE attacks anticipated 1H2026. Data from RAPIDe-3 
      and RAPIDe-2 will serve as the basis for the NDA of deucrictibant, which 
      is on-track to be submitted in the first half of 2026. 
 
   -- Enrollment in CREAATE (NCT07266805) progressing as planned. CREAATE is a 
      global, pivotal Phase 3 study evaluating orally administered 
      deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH 
      attacks. In part 1 of CREAATE, participants receive either deucrictibant 
      XR (40 mg) or placebo once daily for the prophylactic treatment of 
      AAE-C1INH attacks. In part 2 of CREAATE, participants treat two attacks 
      in a crossover fashion, one attack with deucrictibant IR (20 mg) and one 
      with placebo according to a randomized treatment sequence, for the 
      on-demand treatment of AAE-C1INH attacks. Part 3 of CREAATE is the 
      open-label extension portion of the study assessing the long-term safety 
      and effectiveness of deucrictibant IR (20 mg) for on-demand treatment of 
      AAE-C1INH attacks. 
 
   -- Data from RAPIDe-3 support the potentially differentiated profile of 
      deucrictibant for the on-demand treatment of HAE attacks. Data from the 
      pivotal global Phase 3 study (NCT06343779) were presented in a featured 
      posted at the American Academy of Allergy, Asthma & Immunology (AAAAI) 
      2026 Annual Meeting. RAPIDe-3 met the primary and all 11 secondary 
      efficacy endpoints with high statistical significance with deucrictibant 
      achieving onset of symptom relief in 1.28 hours and complete symptom 
      resolution in 11.95 hours (median times), confirming its potentially 
      differentiated profile for the treatment of HAE attacks versus placebo. 

Upcoming Participation at Investor Conferences

   -- BofA Securities Health Care Conference 2026. Las Vegas, NV, May 12-14, 
      2026. 
 
          -- Format: Fireside ChatDate, time: Wednesday, May 13, 8:40 a.m. PDT 
             (11:40 a.m. EDT) 
 
   -- 2026 RBC Capital Markets Global Healthcare Conference. New York, NY, May 
      19-20, 2026. 
 
          -- Format: Fireside ChatDate, time: Wednesday, May 20, 11:00 a.m. EDT 

Financials

Fourth Quarter and Full Year 2025 Financial Results

   -- Liquidity Position. Cash and cash equivalents were EUR292 million as of 
      December 31, 2025, compared to EUR281 million for December 31, 2024. 
 
   -- Research and Development (R&D) Expenses. R&D expenses were EUR34.1 
      million for the fourth quarter and EUR124 million for the full year of 
      2025, compared to EUR31.2 million for the fourth quarter and EUR98.6 
      million for the full year of 2024. 
 
   -- General and Administrative (G&A) Expenses. G&A expenses were EUR13.5 
      million for the fourth quarter and EUR45.3 million for the full year of 
      2025, compared to EUR13.9 million for the fourth quarter and EUR47.1 
      million for the full year of 2024. 
 
   -- Loss for the year. Loss for the fourth quarter of 2025 was EUR46.7 
      million, resulting in basic and diluted loss per share of EUR0.72. For 
      the full year of 2025, loss was EUR176 million, resulting in basic and 
      diluted loss per share of EUR2.97 per share. This compares to EUR34.8 
      million, or basic and diluted loss per share of EUR0.64 for the fourth 
      quarter of 2024, and EUR134 million, or basic and diluted loss per share 
      of EUR2.48, for the full year of 2024. 

About Deucrictibant

Deucrictibant is a novel, potent, orally bioavailable small-molecule bradykinin B2 receptor antagonist currently in clinical development. Deucrictibant is being investigated for its potential to prevent the occurrence of bradykinin-mediated angioedema attacks and to treat the manifestations of attacks if/when they occur by inhibiting bradykinin signaling through the bradykinin B2 receptor. Pharvaris is developing two formulations of deucrictibant for oral administration: an extended-release tablet to enable sustained absorption and efficacy as prophylactic treatment, and an immediate-release capsule to enable rapid onset of activity for on-demand treatment. Deucrictibant has been granted orphan drug designation for the treatment of bradykinin-mediated angioedema by the U.S. Food and Drug Administration, the European Commission, and Swissmedic.

About Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris' aspiration is to offer therapies with injectable-like efficacy$(TM)$, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit https://pharvaris.com/.

Forward Looking Statements

This press release contains certain forward-looking statements that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements relating to our future plans, studies and trials, and any statements containing the words "believe," "anticipate," "expect, " "hope," "estimate," "may," "could," "should," "would," "will," "intend" and similar expressions. These forward-looking statements are based on management's current expectations, are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause Pharvaris' actual results, performance or achievements to be materially different from its expectations expressed or implied by the forward-looking statements. Such risks include but are not limited to the following: uncertainty in the outcome of our interactions with regulatory authorities, including the FDA; the expected timing, progress, or success of our clinical development programs, especially for deucrictibant immediate-release capsules and deucrictibant extended-release tablets, which are in late-stage global clinical trials; our ability to replicate the efficacy and safety demonstrated in the RAPIDe-1, RAPIDe-2, RAPIDe-3, and CHAPTER-1 Phase 2 and Phase 3 studies in ongoing and future nonclinical studies and

clinical trials, such as CHAPTER-3, and CREAATE; the timing and outcome of regulatory approvals, including the timing and outcome of our planned submission of an NDA with the FDA in the first half of 2026 for the on-demand treatment of acute attacks of HAE; risks arising from epidemic diseases, which may adversely impact our business, nonclinical studies, and clinical trials; our ability to potentially use deucrictibant for alternative purposes, for example to treat C1-INH deficiency (AAE-C1INH); the value of our ordinary shares; the timing, costs and other limitations involved in obtaining regulatory approval for our product candidates, or any other product candidate that we may develop in the future; our ability to establish commercial capabilities or enter into agreements with third parties to market, sell, and distribute our product candidates; our ability to compete in the pharmaceutical industry, including with respect to existing therapies, emerging potentially competitive therapies and with competitive generic products; our ability to market, commercialize and achieve market acceptance for our product candidates; our ability to produce sufficient amounts of drug product candidates for commercialization; our ability to raise capital when needed and on acceptable terms; regulatory developments in the United States, the European Union and other jurisdictions; our ability to protect our intellectual property and know-how and operate our business without infringing the intellectual property rights or regulatory exclusivity of others; our ability to manage negative consequences from changes in applicable laws and regulations, including tax laws (including the Biosecure Act), our ability to maintain an effective system of internal control over financial reporting; changes and uncertainty in general market conditions; disruptions at the FDA and other agencies; changes and uncertainty in general market, political and economic conditions, including as a result of inflation and geopolitical conflicts; changes in regulations and customs, tariffs and trade barriers; and the other factors described under the headings "Cautionary Statement Regarding Forward-Looking Statements" and "Item 3. Key Information--D. Risk Factors" in our Annual Report on Form 20-F and other periodic filings with the U.S. Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. While Pharvaris may elect to update such forward-looking statements at some point in the future, Pharvaris disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Pharvaris' views as of any date subsequent to the date of this press release.

Contact 
Maggie Beller 
Vice President, Head of Corporate and Investor Communications 
maggie.beller@pharvaris.com 

(END) Dow Jones Newswires

April 02, 2026 06:50 ET (10:50 GMT)